Exploring the causal relationship between antihypertensive drugs and glioblastoma by combining drug target Mendelian randomization study, eQTL colocalization, and single-cell RNA sequencing
Related Experiment Video
Updated: May 5, 2026

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Songyun Zhao1,2, Yi Xie3, Xu Ding2
1Department of Neurosurgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
Abstract:
Recent reports indicate a potential oncogenic role of antihypertensive drugs in common cancers. However, it remains uncertain whether this phenomenon influences the risk of glioblastoma multiforme (GBM). This study aimed to assess the potential causal effects of blood pressure (BP) and antihypertensive drugs on GBM. Genome-wide association study (GWAS) summary statistics for systolic blood pressure (SBP), diastolic blood pressure (DBP), and GBM in Europeans were downloaded. To represent the effects of antihypertensive drugs, we utilized single nucleotide polymorphisms (SNPs) associated with SBP/DBP adjacent to the coding regions of different antihypertensive drugs as instrumental variables to model five antihypertensive drugs, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, β-receptor blockers (BBs), and thiazide diuretics. Positive control studies were performed using GWAS data in chronic heart failure. The primary method for causality estimation was the inverse-variance-weighted method. Mendelian randomization analysis showed that BBs with the β1-adrenergic receptor (ADRB1) as a therapeutic target could significantly reduce the risk of GBM by mediating DBP (OR = 0.431, 95% CI: 0.267-0.697, p < .001) and that they could also significantly reduce the risk of GBM by mediating SBP (OR = 0.595, 95% CI: 0.422-0.837, p = .003). Sensitivity analysis and colocalization analysis reinforced the robustness of these findings. Finally, the low expression of the ADRB1 gene in malignant gliomas was found by GBM data from TCGA and single-cell RNA sequencing, which most likely contributed to the poor prognosis of GBM patients. In summary, our study provides preliminary evidence of some causal relationship between ADRB1-targeted BBs and glioblastoma development. However, more studies are needed to validate these findings and further reveal the complex relationship between BP and GBM.
Insights
Beta-blockers (BBs) targeting the β1-adrenergic receptor (ADRB1) may reduce glioblastoma multiforme (GBM) risk by lowering blood pressure. Lower ADRB1 gene expression in malignant gliomas correlates with poor prognosis, suggesting a link between BBs and GBM development.
Area of Science:
- Genetics and Genomics
- Oncology
- Pharmacology
Background:
- Emerging evidence suggests antihypertensive drugs may play a role in cancer development.
- The specific impact of these drugs on glioblastoma multiforme (GBM) risk remains unclear.
- Understanding the relationship between blood pressure, antihypertensive medications, and GBM is crucial for patient outcomes.
Purpose of the Study:
- To investigate the potential causal relationship between blood pressure (BP) and GBM risk.
- To assess the influence of specific antihypertensive drug classes on GBM development.
- To explore the role of the β1-adrenergic receptor (ADRB1) in GBM pathogenesis.
Main Methods:
- Utilized genome-wide association study (GWAS) summary statistics for systolic BP (SBP), diastolic BP (DBP), and GBM in European populations.
- Employed Mendelian randomization analysis with single nucleotide polymorphisms (SNPs) as instrumental variables for five antihypertensive drug classes.
- Performed sensitivity and colocalization analyses to confirm findings; analyzed ADRB1 gene expression in GBM using TCGA and single-cell RNA sequencing data.
Main Results:
- β-receptor blockers (BBs) targeting ADRB1 significantly reduced GBM risk by mediating both DBP (OR=0.431) and SBP (OR=0.595).
- Sensitivity and colocalization analyses supported the robustness of the observed causal effects.
- Low ADRB1 gene expression was identified in malignant gliomas, correlating with poorer GBM patient prognosis.
Conclusions:
- This study provides preliminary evidence suggesting a causal link between ADRB1-targeted BBs and reduced GBM risk.
- The findings highlight the potential role of ADRB1 in glioblastoma development and prognosis.
- Further research is warranted to validate these results and elucidate the complex interplay between BP management and GBM.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021